Grifols A : Considering Shanghai Raas’ disposal
>Considering the alternatives to cash out Shanghai Raas - According to the Spanish press (finanzas.com) citing sources close to the company, Grifols is considering the options to cash-out its stake in Shanghai Raas whilst at the same time preserving its presence in the Chinese market. These sources also state that the deal could be closed as soon as January 2023 now that Covid restrictions in China have been relaxed.The disposal has deleveraging potential...Grifols is engaged in developing, manufacturing and distributing a range of plasma derivative products. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend the lives of individuals who suffer from chronic and acute conditions. Co. also specializes in providing infusion solutions, nutrition products, medical devices, diagnostic instrumentation and reagents for use in hospitals and clinics. Co.'s products and services are used by healthcare providers in approximately 100 countries. Co.'s business is organized into three divisions: Bioscience, Diagnostic, Hospital and Raw Materials.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.